Business / Finance

RSS

Urologix granted additional cure period to regain NASDAQ compliance

Urologix, Inc., announced today that it received a letter, dated February 16, 2011, from The NASDAQ Stock Market notifying Urologix that its request had been granted for an additional 180 calendar day cure period, until August 15, 2011, to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Capital Market,

17 Feb 2011

EMA publishes concept paper on pharmaceutical cold storage conditions during transport

The European Medicines Agency has published a concept paper on storage conditions during transport. The goal is to create new Good Distribution Practice and GMP guidance and may lead to the need to revise the guideline on declaration of storage conditions.

From IQPC Ltd 17 Feb 2011

Omega fourth quarter net income decreases to $5.0 million

Omega Healthcare Investors, Inc. today announced its results of operations for the quarter and fiscal year ended December 31, 2010. The Company also reported Funds From Operations ("FFO") available to common stockholders for the three months ended December 31, 2010 of $28.4 million or $0.29 per common share.

17 Feb 2011

Celgene board authorizes additional $1 billion share repurchase

Celgene Corporation today announced that the company's Board of Directors has authorized the repurchase of up to an additional $1 billion of the Company's common stock through December 2012.

17 Feb 2011

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

17 Feb 2011

Advaxis added to Mentor Capital Cancer Immunotherapy Index

Mentor Capital, Inc. reports that Advaxis, Inc. has been added as the newest member of the Mentor Capital Cancer Immunotherapy Index.

16 Feb 2011

Orexo fourth quarter net revenues increase to MSEK 109.1

Abstral continues to grow strongly and is now also approved in the USA. OX-MPI has made significant progress towards clinical trials and has received its first milestone payment. The three new programs OX219, OX51 and OX27 announced in August 2010 have now all entered the clinical phase.

16 Feb 2011

Activaero closes financing round for € 5.0 million

Activaero GmbH, a technology leader in controlled breathing inhalation devices, today announced that it has closed a further financing round of € 5.0 million.

16 Feb 2011

CTI's fourth quarter net loss increases to $34.1 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2010.

16 Feb 2011

AMT 2010 total net income increases to EUR 1.4 million

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the year to December 31, 2010.

16 Feb 2011

Sanofi-aventis enters definitive agreement to acquire Genzyme

Sanofi-aventis and Genzyme Corporation announced today that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion.

16 Feb 2011

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Sanofi-aventis and Sunnybrook Health Sciences Centre announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack of sensation and neuropathic ulcers that are complicated by peripheral arterial disease, commonly called neuroischemic diabetic foot ulcers.

16 Feb 2011

Fibrocell Science sells $7.8 million Series D convertible preferred stock

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that between December 8, 2010 and February 9, 2011 it entered into agreements with certain accredited investors, pursuant to which the Company sold to the purchasers in the aggregate approximately $7.8 million of the Company's Series D convertible preferred stock, which is convertible into shares of common stock at a conversion price of $0.50 per share.

16 Feb 2011

Thermo Fisher Scientific extends tender offer for Dionex

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its previously announced tender offer to acquire all of the outstanding shares of Dionex Corporation for $118.50 per share in cash has been extended and will now expire at 12:00 midnight, New York City time, at the end of Thursday, April 7, 2011, unless further extended.

From Thermo Fisher Scientific Inc. 16 Feb 2011

Orabrush closes $2.5 million investment round

Orabrush, the tongue cleaner that helps cure bad breath, today announced that the company has closed a $2.5 million investment round with True Ventures of Palo Alto and returning investor 2x Consumer Products Growth Partners of Chicago. Funds will be used to help further accelerate the company's retail growth by maximizing its exceptional online brand and expanding its retail partnerships and distribution channels throughout the world.

16 Feb 2011

Gen-Probe board authorizes $150 million stock repurchase

Gen-Probe Incorporated announced today that its board of directors has authorized the repurchase of up to $150 million of the Company's common stock over the next year.

16 Feb 2011

Orthofix 2010 net sales increase 3% to $564.4 million

Orthofix International N.V. today announced its results for the fourth quarter and year ended December 31, 2010.

16 Feb 2011

Benchmark signs definitive agreement to form $890 million partnership with Health Care REIT

Benchmark Senior Living, the leading provider of senior living services in the Northeast, announced today that it has signed a definitive agreement to form an $890 million partnership with Health Care REIT, Inc., an S&P 500 company that invests across the full spectrum of senior housing and health care real estate.

16 Feb 2011

UMB achieves 35% increase in health spending accounts

UMB Healthcare Services, a division of UMB Financial Corporation, announced today that it has achieved a 35 percent increase in the number of its health spending accounts.

15 Feb 2011

Prime Health Services acquires Applied Metrics

Prime Health Services, one of the nation's largest workers' compensation, group health, and first party auto liability PPO networks, is pleased to announce it has acquired majority interest in Applied Metrics.

15 Feb 2011